Genmab — Februar 2019

[E_L]

that is not news to us

[E_L]

it is to the market apparently.

[Bulder]

Det får minimal betydning. Det er for det første 2. linje og så går det ud på at finde ud af om man kan stoppe behandlingen efter 24 mdr. eller om den skal fortsætte indtil relaps. Men ingen kender endnu svaret.

[Bulder]

301 Moved Permanently

(www.clinicaltrials.gov)

[E_L]

and it will take 6 years for the study to complete

[Plimsoller]

Not 4 years E L?

[Bulder]

If they start recruiting coming March, they'll have the first OS-data in 4 years. But that will not be enough to conclude. They'll have to wait for a significant result. Closer to 6 years.

[Solsen]

Not news and I belive no significant influence on the sales. Far far out in future.

[Solsen]

And after 6 years it will take another two years to make any difference on new start ups.

[Solsen]

Now we are two days from where we will se if shorters can hold Genmab from breaking up.

[hda]

Hopefully you are right Solsen

[nohope]

Well, I don´t know who to blame but today wasn´t too good - unless you are short.

[Tandfeen-2]

Håber hver gang jeg checker mails at der er besked fra Genmab om godkendt 1. Linje USA. Er jeg den eneste?

[Solsen]

Hvilken behandling er egentlig på labelen i 2. line. Er det annoncerede forsøg egentlig en begrænsning eller udvidelse. Tror ikke analytikerne medregner megen maintenance i darasalget.

[E_L]

I actually think there is a bigger chance for combination therapy to scale down to only daratumumab after a certain time, very well tolerated and much cheaper as the combo. Time will tell.

[Solsen]

The dose scedule is the same as Alcyone. And yes EL thats what mr Darzalex, dr Plesner, have said

[E_L]

we could use another video from mr Darzalex to boost the morale

[E_L]

Not Always Imperative to Change Drug Class After Disease Progression, Myeloma Expert Says https://www.targetedonc.com/news/not-always-imperative-to-change-drug-class-after-disease-progression-myeloma-expert-says

[Bulder]

Studiets rationale er primært økonomisk: Hvis det alligevel ikke gi'r noget ekstra for pt at køre ud over 24 mdr., så kan vi jo lige så godt stoppe der og spare de penge. Tiden må så vise om det er rigtigt, og under alle omstændigheder er Rev gået af patent, når studiet er færdigt.

[StockBull]

Jefferies er normalt positiv paa Genmab. Underligt at dette studie bekymre dem